Neuromodulation device
US-2020009384-A1 · Jan 9, 2020 · US
Compounds and methods for treating neurological and cardiovascular conditions
US12239654B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12239654-B2 |
| Application number | US-201716095282-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 21, 2017 |
| Priority date | Apr 21, 2016 |
| Publication date | Mar 4, 2025 |
| Grant date | Mar 4, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.
First claim
Opening claim text (preview).
We claim: 1. A method of treating an injury, disease, or condition selected from traumatic brain injury (TBI) and a stroke selected from ischemic stroke, hemorrhagic stroke, subarachnoid hemorrhage, cerebral vasospasm, and transient ischemic attacks (TIA), comprising administering to a patient in need thereof an effective amount of a compound selected from: or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , wherein the injury, disease, or condition is TBI. 3. The method of claim 2 , wherein the TBI is selected from concussion, blast injury, combat-related injury, or a mild, moderate or severe blow to the head. 4. The method of claim 1 , wherein the recovery period after the TBI or stroke is decreased as compared with an untreated patient. 5. The method of claim 1 , wherein the compound is administered chronically to treat stroke during the time period after the injury has occurred as it resolves. 6. The method of claim 1 , wherein the compound is selected from: or a pharmaceutically acceptable salt thereof. 7. The method of claim 1 , wherein the injury, disease, or condition is stroke and the compound or pharmaceutically acceptable salt thereof is administered within 48 hours of the stroke. 8. The method of claim 1 , wherein the injury, disease, or condition is stroke and the compound or pharmaceutically acceptable salt thereof is administered within 24 hours of the stroke. 9. The method of claim 1 , wherein the injury, disease, or condition is TBI and the compound or pharmaceutically acceptable salt thereof is administered within 48 hours of the TBI. 10. The method of claim 1 , wherein the injury, disease, or condition is TBI and the compound or pharmaceutically acceptable salt thereof is administered within 24 hours of the TBI. 11. The method of claim 2 , wherein neuroprotection or neurorestoration is increased in the patient as compared with an untreated patient.
Assignees
Inventors
Classifications
- A61K31/519Primary
ortho- or peri-condensed with heterocyclic rings · CPC title
Drugs for disorders of the nervous system · CPC title
- A61K31/52Primary
Purines, e.g. adenine · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Anti-Parkinson drugs · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12239654B2 cover?
- The present invention relates to compounds and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.
- Who is the assignee on this patent?
- Astrocyte Pharmaceuticals Inc, Univ Texas, Us Health
- What technology area does this patent fall under?
- Primary CPC classification A61K31/519. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).